Literature DB >> 29414509

Ultrasonic histogram assessment of early response to concurrent chemo-radiotherapy in patients with locally advanced cervical cancer: a feasibility study.

Yan Xu1, Tong Ru2, Lijing Zhu3, Baorui Liu3, Huanhuan Wang4, Li Zhu4, Jian He4, Song Liu4, Zhengyang Zhou5, Xiaofeng Yang6.   

Abstract

PURPOSE: To monitor early response for locally advanced cervical cancers undergoing concurrent chemo-radiotherapy (CCRT) by ultrasonic histogram.
METHODS: B-mode ultrasound examinations were performed at 4 time points in thirty-four patients during CCRT. Six ultrasonic histogram parameters were used to assess the echogenicity, homogeneity and heterogeneity of tumors.
RESULTS: Ipeak increased rapidly since the first week after therapy initiation, whereas Wlow, Whigh and Ahigh changed significantly at the second week. The average ultrasonic histogram progressively moved toward the right and converted into more symmetrical shape.
CONCLUSION: Ultrasonic histogram could be served as a potential marker to monitor early response during CCRT.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Concurrent chemo-radiotherapy; Therapy response; Ultrasonic histogram

Mesh:

Year:  2018        PMID: 29414509     DOI: 10.1016/j.clinimag.2018.01.002

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  2 in total

1.  Value of Histogram of Gray-Scale Ultrasound Image in Differential Diagnosis of Small Triple Negative Breast Invasive Ductal Carcinoma and Fibroadenoma.

Authors:  Maolin Xu; Fang Li; Shaonan Yu; Shue Zeng; Gaolong Weng; Peihong Teng; Huimin Yang; Xuefeng Li; Guifeng Liu
Journal:  Cancer Manag Res       Date:  2022-04-21       Impact factor: 3.602

2.  Ultrasonographic diagnosis in rare primary cervical cancer.

Authors:  Jiaoling Li; Congmin Gu; Haiqing Zheng; Xiuping Geng; Zhonghan Yang; Lin Zhou; Haiying Wu
Journal:  Int J Gynecol Cancer       Date:  2021-10-28       Impact factor: 3.437

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.